Fulcrum Therapeutics, Inc. (FULC)
3.77
-0.02
(-0.53%)
USD |
NASDAQ |
Sep 17, 16:00
3.775
0.00 (0.00%)
Pre-Market: 20:00
Fulcrum Therapeutics Cash from Operations (Quarterly) : -16.04M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -16.04M |
| March 31, 2026 | -18.75M |
| December 31, 2025 | -16.80M |
| September 30, 2025 | -14.19M |
| June 30, 2025 | -13.82M |
| March 31, 2025 | -15.26M |
| December 31, 2024 | -16.76M |
| September 30, 2024 | -19.07M |
| June 30, 2024 | 58.90M |
| March 31, 2024 | -25.28M |
| December 31, 2023 | -23.16M |
| September 30, 2023 | -22.91M |
| June 30, 2023 | -20.78M |
| March 31, 2023 | -24.12M |
| December 31, 2022 | -19.70M |
| September 30, 2022 | -27.88M |
| June 30, 2022 | -27.37M |
| Date | Value |
|---|---|
| March 31, 2022 | -22.11M |
| December 31, 2021 | -21.86M |
| September 30, 2021 | -22.57M |
| June 30, 2021 | -17.82M |
| March 31, 2021 | -16.23M |
| December 31, 2020 | -19.83M |
| September 30, 2020 | -4.504M |
| June 30, 2020 | -14.12M |
| March 31, 2020 | -15.20M |
| December 31, 2019 | -4.495M |
| September 30, 2019 | -13.02M |
| June 30, 2019 | -12.07M |
| March 31, 2019 | -9.897M |
| December 31, 2018 | -6.403M |
| September 30, 2018 | -4.12M |
| June 30, 2018 | -5.407M |
| March 31, 2018 | -6.632M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | -2.536M |
| CNBX Pharmaceuticals, Inc. | -0.0477M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | -48.30M |
| Definium Therapeutics, Inc. | -52.33M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 13.78M |
| Cash from Financing (Quarterly) | 0.356M |
| Free Cash Flow | -66.14M |
| Free Cash Flow Per Share (Quarterly) | -0.2117 |
| Free Cash Flow to Equity (Quarterly) | -15.56M |
| Free Cash Flow to Firm (Quarterly) | -16.15M |
| Free Cash Flow Yield | -24.99% |